Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Pakistan Journal of Pharmaceutical Sciences. 2018; 31 (3): 747-754
em Inglês | IMEMR | ID: emr-198657

RESUMO

Pioglitazone, peroxisome proliferator-activated receptor [PPAR-gamma] agonist, is a therapeutic drug for diabetes. Present study investigated the interaction between PPAR-gamma and alpha adrenoceptors in modulating vasopressor responses to Angiotensin II [Ang II] and adrenergic agonists, in diabetic and non-diabetic Spontaneously Hypertensive Rats [SHRs]. Diabetes was induced with an i.p injection of streptozotocin [40 mg/kg] in two groups [STZ-CON, STZ-PIO], whereas two groups remained non diabetic [ND-CO, ND-PIO]. One diabetic and non-diabetic group received Pioglitazone [10mg/kg] orally for 21 days. On day 28, the animals were anaesthetized with sodium pentobarbitone [60mg/kg] and prepared for measurement of systemic haemodynamics. Basal mean arterial pressure of STZ-CON was higher than NDCON, whereas following pioglitazone treatment, MAP was lower compared to respective controls. MAP responses to i.v administration of NA, PE, ME and ANG II were significantly lower in diabetic SHRs: STZ-CON vs. ND-CON [35%]. Pioglitazone significantly decreased responses to NA, PE, ME and ANG II in ND-PIO versus ND-CON by 63%. Responses to NA and ANG II were significantly attenuated in STZ-PIO vs. ND-PIO [40%]. PPAR-gamma regulates systemic hemodynamic in diabetic model and cross-talk relationship exists between PPAR-gamma and alpha1-adrenoceptors, ANG II in systemic vasculature of SHRs

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA